A Phase 1 interventional study of Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 and Glycopyrronium and Formoterol Fumarate (GFF) Dose 2 in COPD, sponsored by Pearl Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-26.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 173rd largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 42 in phase 1, and was the 156th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 14 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over, Single-Center, Phase I, Crossover Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Form (ICF) prior to any study related procedures
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
Drug: Glycopyrronium (GP) Dose 1
Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
Drug: Glycopyrronium (GP) Dose 2
Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
Cmax
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (Cmax)
Time frame: Day 1
Cmax
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (Cmax)
Time frame: Day 1
AUC 0-12
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-12)
Time frame: Day 1
AUC 0-12
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-12)
Time frame: Day 1
AUC 0-t
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-t)
Time frame: Day 1
AUC 0-t
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-t)
Time frame: Day 1
AUC 0-∞
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-∞)
Time frame: Day 1
AUC 0-∞
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-∞)
Time frame: Day 1
Tmax
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (tmax)
Time frame: Day 1
Tmax
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (tmax)
Time frame: Day 1
T 1/2
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (T 1/2)
Time frame: Day 1
T 1/2
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (T 1/2)
Time frame: Day 1
CL/F
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment
Time frame: Day 1
CL/F
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
Time frame: Day 1
Vd/F
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrroniuml by Treatment
Time frame: Day 1
Vd/F
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
Time frame: Day 1
Lambda z
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment
Time frame: Day 1
Lambda z
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
Time frame: Day 1
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose
Time frame: 12 Hours
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar volume)
Time frame: 12 Hours
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar hemoglobin)
Time frame: 12 Hours
Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Erythrocytes)
Time frame: 12 Hours
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose
Time frame: 12 hours
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (eGFR)
Time frame: 12 hours
Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ferritin)
Time frame: 12 hours
Change in Mean Glucose and Potassium Results (±SD) From Pre-dose to 12 Hours Post-dose
Change in Mean Glucose and Potassium Results (±SD) from Pre-dose to 12 Hours Post-dose
Time frame: 12 hours
Change in Heart Rate From Pre-dose to 12 Hours Post Dose
Change in Heart Rate from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in PR Interval From Pre-dose to 12 Hours Post Dose
Change in PR Interval from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in QRS Axis From Pre-dose to 12 Hours Post Dose
Change in QRS axis from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in QRS Duration From Pre-dose to 12 Hours Post Dose
Change in QRS duration from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in QT Interval From Pre-dose to 12 Hours Post Dose
Change in QT Interval from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose
Change in QTc Bazett Interval from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose
Change in QTc Fridericia's Interval from Pre-dose to 12 hours Post dose
Time frame: 12 hours
Conducted at 1 site from July 2014 - September 2014. Study duration for each subject was between 33 and 98 days.
| Milestone | Received GFF MDI 28.8/9.6 μg | Received GFF MDI 14.4/9.6 μg | Received GP MDI 28.8 μg | Received GP MDI 14.4 μg |
|---|---|---|---|---|
| Started | 24 | 23 | 24 | 24 |
| Completed | 24 | 23 | 23 | 24 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (Cmax)
| pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 µg |
|---|---|---|---|---|
| Cmax | 15.23 ± 7.69 | 9.09 ± 6.5 | 16.85 ± 4.26 | 7.26 (2.51 to 16.10) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (Cmax)
| pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| Cmax | 10.74 ± 3.46 | 11.99 ± 7.07 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-12)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 ug |
|---|---|---|---|---|
| AUC 0-12 | 45.43 ± 19.43 | 21.75 ± 9.00 | 50.59 ± 10.75 | 24.72 (7.63 to 51.06) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-12)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| AUC 0-12 | 44.15 ± 15.3 | 42.54 ± 12.04 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-t)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 µg |
|---|---|---|---|---|
| AUC 0-t | 53.52 ± 3.31 | 21.37 ± 14.53 | 64.05 ± 17.61 | 23.72 (5.27 to 68.02) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-t)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| AUC 0-t | 45.96 ± 19.85 | 42.39 ± 14.69 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (AUC 0-∞)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 µg | GP MDI 14.4 µg |
|---|---|---|---|---|
| AUC 0-∞ | 46.26 (29.58 to 60.11) | 32.18 (30.24 to 34.13) | 37.32 (32.36 to 42.28) | 34.04 (33.67 to 34.64) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (AUC 0-∞)
| h*pg/mL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| AUC 0-∞ | 61.88 ± 21.60 | 61.43 ± 12.01 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (tmax)
| h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 ug |
|---|---|---|---|---|
| Tmax | 0.10 (0.03 to 4.02) | 0.10 (0.03 to 0.10) | 0.10 (0.03 to 2.00) | 0.10 (0.03 to 4.10) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (tmax)
| h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| Tmax | 0.10 (0.10 to 1.00) | 0.10 (0.10 to 2.00) |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment (T 1/2)
| h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 ug |
|---|---|---|---|---|
| T 1/2 | 9.49 ± 11.98 | 4.14 ± 1.40 | 24.87 ± 51.77 | 19.13 (2.08 to 191.29) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment (T 1/2)
| h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| T 1/2 | 5.45 ± 2.39 | 5.25 ± 2.32 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment
| L/h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 µg | GP MDI 14.4 µg |
|---|---|---|---|---|
| CL/F | 657.91 (479.15 to 973.62) | 449.10 (421.97 to 476.24) | 785.60 (681.20 to 890.00) | 423.12 (415.74 to 427.70) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
| L/h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| CL/F | 168.95 ± 45.28 | 161.55 ± 30.17 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrroniuml by Treatment
| L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 µg | GP MDI 14.4 µg |
|---|---|---|---|---|
| Vd/F | 3508.00 (2089.69 to 4654.28) | 2577.78 (2475.12 to 2680.44) | 3555.88 (3509.62 to 3602.14) | 2101.03 (1929.07 to 2193.02) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
| L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| Vd/F | 1187.75 ± 313.20 | 1054.16 ± 225.15 |
Descriptive Statistics for Pharmacokinetic Parameters of Glycopyrronium by Treatment
| 1/h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 ug |
|---|---|---|---|---|
| Lambda z | 0.1506 ± 7.69 | 0.1983 ± 6.5 | 0.1100 ± 4.26 | 0.1614 (0.0036 to 0.3333) |
Descriptive Statistics for Pharmacokinetic Parameters of Formoterol by Treatment
| 1/h | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug |
|---|---|---|
| Lambda z | 0.1412 ± 0.0381 | 0.1470 ± 0.0410 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| 10^9cells/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Basophils (10^9cells/L) | 0.007 ± 0.025 | 0.000 ± 0.022 | 0.001 ± 0.028 |
| Eosinophils (10^9cells/L) | 0.044 ± 0.048 | 0.033 ± 0.068 | 0.065 ± 0.103 |
| Granulocytes (10^9cells/L) | 0.222 ± 1.436 | 0.483 ± 1.793 | 0.443 ± 1.278 |
| Leukocytes (10^9cells/L) | 0.484 ± 1.710 | 0.780 ± 1.990 | 0.800 ± 1.526 |
| Lymphocytes (10^9cells/L) | 0.147 ± 0.390 | 0.206 ± 0.402 | 0.235 ± 0.383 |
| Monocytes (10^9cells/L) | 0.065 ± 0.084 | 0.056 ± 0.115 | 0.055 ± 0.103 |
| Platelets (10^9cells/L) | -22.4 ± 24.5 | -14.4 ± 16.2 | -23.1 ± 26.6 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| Ratio | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Basophils/leukocytes (ratio) | -0.0001 ± 0.0044 | -0.0013 ± 0.0040 | -0.0013 ± 0.0039 |
| Eosinophils/leukocytes (ratio) | 0.0034 ± 0.0089 | 0.0026 ± 0.0131 | 0.0046 ± 0.0091 |
| Granulocytes/leukocytes (ratio) | 0.0043 ± 0.0688 | 0.0003 ± 0.0818 | -0.0010 ± 0.0759 |
| Hematocrit (ratio) | -0.040 ± 0.022 | -0.041 ± 0.030 | -0.043 ± 0.023 |
| Lymphocytes/leukocytes (ratio) | -0.0110 ± 0.0565 | -0.0019 ± 0.0662 | -0.0018 ± 0.0616 |
| Monocytes/leukocytes (ratio) | 0.0034 ± 0.0125 | 0.0004 ± 0.0136 | -0.0006 ± 0.0118 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| g/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Ery. mean corpuscuar HGB (g/L) | 12.0 ± 15.5 | 8.5 ± 13.9 | 11.4 ± 15.2 |
| Hemoglobin (g/L) | -8.81 ± 7.76 | -10.61 ± 9.10 | -10.38 ± 9.10 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar volume)
| fL | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose | -0.9 ± 0.6 | -0.8 ± 0.9 | -0.9 ± 0.8 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ery. mean corpuscuar hemoglobin)
| pg/cell | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose | 0.78 ± 1.29 | 0.49 ± 1.08 | 0.75 ± 1.22 |
Change in Mean Hematology Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Erythrocytes)
| 10^12cells/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose | -0.391 ± 0.242 | -0.419 ± 0.326 | -0.433 ± 0.253 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| IU/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| ALT (IU/L) | -3.1 ± 4.3 | -1.7 ± 3.1 | -2.4 ± 3.9 |
| Alkaline phosphatase (IU/L) | -5.2 ± 4.3 | -5.0 ± 5.1 | -6.0 ± 3.1 |
| AST (IU/L) | -4.2 ± 3.7 | -3.3 ± 2.6 | -3.7 ± 3.0 |
| Gamma glutamyl transferase (IU/L) | -2.5 ± 2.4 | -1.6 ± 1.9 | -2.2 ± 1.9 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| g/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Albumin (g/L) | -7.1 ± 2.9 | -6.9 ± 4.1 | -6.7 ± 2.4 |
| Protein (g/L) | -10.9 ± 5.3 | -10.8 ± 6.7 | -10.3 ± 4.3 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| mmol/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Blood urea nitrogen (mmol/L) | 0.01 ± 1.45 | 0.34 ± 1.32 | 0.74 ± 1.51 |
| Calcium (mmol/L) | -0.15 ± 0.09 | -0.14 ± 0.12 | -0.13 ± 0.06 |
| Chloride (mmol/L) | 3.0 ± 2.3 | 2.5 ± 1.8 | 2.3 ± 1.5 |
| Magnesium (mmol/L) | -0.05 ± 0.09 | -0.07 ± 0.09 | -0.04 ± 0.20 |
| Phosphorus (mmol/L) | 0.135 ± 0.165 | 0.163 ± 0.132 | 0.133 ± 0.164 |
| Sodium (mmol/L) | 0.9 ± 2.1 | 0.5 ± 1.3 | 0.1 ± 1.6 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose
| μmol/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Creatinine (μmol/L) | 1.88 ± 11.14 | 4.92 ± 15.74 | 3.61 ± 13.41 |
| Direct bilirubin (μmol/L) | -3.06 ± 1.75 | -2.53 ± 1.45 | -2.64 ± 2.14 |
| Iron (μmol/L) | -5.42524 ± 8.9 | -2.81888 ± 7.07702 | -2.58949 ± 8.19974 |
| Total bilirubin (μmol/L) | -8.19 ± 5.68 | -7.14 ± 4.80 | -7.20 ± 5.92 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (eGFR)
| mL/min/1.73m2 | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose | -4.2 ± 13.2 | -7.2 ± 16.6 | -3.5 ± 15.3 |
Change in Mean Chemistry Parameters (±SD) from Pre-dose to 12 Hours Post-dose (Ferritin)
| μg/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose | -14.169 ± 13.912 | -11.949 ± 12.306 | -11.669 ± 9.731 |
Change in Mean Glucose and Potassium Results (±SD) from Pre-dose to 12 Hours Post-dose
| mmol/L | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Glucose (mmol/L) 30 minutes post-dose | -0.03 (-0.3 to 0.6) | -0.08 (-0.8 to 0.5) | -0.01 (-0.4 to 0.7) |
| Glucose (mmol/L) 2 hours post-dose | 0.05 (-0.3 to 0.4) | -0.01 (-0.7 to 0.8) | -0.06 (-0.4 to 0.7) |
| Glucose (mmol/L) 4 hours post-dose | -0.08 (-0.5 to 0.4) | -0.24 (-0.8 to 0.4) | -0.16 (-0.6 to 0.7) |
| Glucose (mmol/L) 12 hours post-dose | 0.10 (-0.4 to 0.7) | 0.18 (-0.8 to 0.8) | 0.23 (-0.3 to 0.9) |
| Potassium (mmol/L) 30 minutes post-dose | 0.01 (-0.3 to 1.0) | 0.00 (-0.6 to 0.5) | 0.06 (-0.5 to 0.9) |
| Potassium (mmol/L) 2 hours post-dose | -0.02 (-0.5 to 0.8) | -0.07 (-0.5 to 0.4) | 0.10 (-0.4 to 2.4) |
| Potassium (mmol/L) 4 hours post-dose | -0.01 (-0.6 to 1.0) | -0.12 (-0.5 to 0.4) | -0.07 (-0.6 to 0.4) |
| Potassium (mmol/L) 12 hours post-dose | 0.05 (-0.5 to 0.7) | -0.06 (-0.6 to 0.4) | 0.07 (-0.5 to 1.0) |
Change in Heart Rate from Pre-dose to 12 hours Post dose
| Beats/Min | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in Heart Rate From Pre-dose to 12 Hours Post Dose | 11.3 (2 to 42) | 9.3 (-4 to 36) | 4.5 (-13 to 29) |
Change in PR Interval from Pre-dose to 12 hours Post dose
| msec | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in PR Interval From Pre-dose to 12 Hours Post Dose | -10.7 (-22 to 6) | -8.5 (-46 to 14) | -7.4 (-36 to 6) |
Change in QRS axis from Pre-dose to 12 hours Post dose
| QRS axis | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in QRS Axis From Pre-dose to 12 Hours Post Dose | -0.5 (-20 to 15) | 4.1 (-11 to 76) | 0.0 (-21 to 16) |
Change in QRS duration from Pre-dose to 12 hours Post dose
| msec | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in QRS Duration From Pre-dose to 12 Hours Post Dose | -3.9 (-24 to 8) | -1.1 (-14 to 6) | -4.0 (-22 to 4) |
Change in QT Interval from Pre-dose to 12 hours Post dose
| msec | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in QT Interval From Pre-dose to 12 Hours Post Dose | -28.5 (-64 to 0) | -24.8 (-78 to 0) | -20.5 (-72 to 24) |
Change in QTc Bazett Interval from Pre-dose to 12 hours Post dose
| msec | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose | 7.2 (-14 to 40) | 4.4 (-26 to 30) | -5.8 (-28 to 10) |
Change in QTc Fridericia's Interval from Pre-dose to 12 hours Post dose
| msec | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug |
|---|---|---|---|
| Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose | -4.8 (-17 to 11) | -5.4 (-27 to 16) | -10.8 (-29 to 5) |
Collected over Adverse Events were collected from Day 0 (Randomization visit and first dose) through Final Follow-up Visit, which is 7-14 days post final dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GFF MDI 28.8/9.6 ug | — | 0/24 (0%) | 2/24 (8.3%) |
| GFF MDI 14.4/9.6 ug | — | 0/23 (0%) | 8/23 (34.8%) |
| GP MDI 28.8 ug | — | 0/24 (0%) | 4/24 (16.7%) |
| GP MDI 14.4 µg | — | 0/24 (0%) | 4/24 (16.7%) |
| Event | GFF MDI 28.8/9.6 ug | GFF MDI 14.4/9.6 ug | GP MDI 28.8 ug | GP MDI 14.4 µg |
|---|---|---|---|---|
| DizzinessNervous system disorders | 0/24 | 2/23 | 2/24 | 0/24 |
| HeadacheNervous system disorders | 0/24 | 2/23 | 1/24 | 1/24 |
| DysmenorrhoeaReproductive system and breast disorders | 0/24 | 2/23 | 0/24 | 1/24 |
| AnaemiaBlood and lymphatic system disorders | 0/24 | 2/23 | 1/24 | 2/24 |
| SomnolenceNervous system disorders | 2/24 | 0/23 | 0/24 | 0/24 |
Analysis Set: All Subjects Randomized
| Age, Continuous(Years) | All Subjects |
|---|---|
| Mean | 29.8 ± 6.5 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 11 |
| Male | 13 |
The record gives a start of Jul 2014 and a primary completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →